Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 380

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 380
---
 ​ | ​ 
 ​ | 2024 
 ​    | ​ |         ​ | ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Six MonthsEnded June 30, 
 2025                             
 ​                                | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2024 
 ​    | ​ |         ​ | ​ | ​ 
 ​ 
 ​ |
|:-------------------------------------------------------------------------------------------|:--|:--|:-----------------------------------|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|:--|:---------------------------------|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|
| Net income (loss) for basic net income (loss) per shareattributable to common stockholders | ​ | ​ | ​                                  | $ |     4,167 | ​ | ​ | ​ | ​    | $ |    -6,975 | ​ | ​ | ​ | ​                                | $ |    -5,412 | ​ | ​ | ​ | ​    | $ |   -11,177 | ​ | ​ |
| Reversal of fair market value remeasurement gainon Convertible Notes﻿(1)                   | ​ | ​ | ​                                  | ​ |   -12,752 | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ | ​ | ​                                | ​ |    -7,810 | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ |
| Add back of interest expense from the Convertible Notes﻿(1)                                | ​ | ​ | ​                                  | ​ |        93 | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ | ​ | ​                                | ​ |       651 | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ |
| Net loss for diluted net loss per share attributable to common stockholders                | ​ | ​ | ​                                  | $ |    -8,492 | ​ | ​ | ​ | ​    | $ |    -6,975 | ​ | ​ | ​ | ​                                | $ |   -12,571 | ​ | ​ | ​ | ​    | $ |   -11,177 | ​ | ​ |
| Denominator: